129 related articles for article (PubMed ID: 15614736)
61. Expression of tumor-associated glycoprotein-72 (TAG-72) antigen in human prostatic adenocarcinomas.
Karan D; Johansson SL; Lin MF; Batra SK
Oncol Rep; 2001; 8(5):1123-6. PubMed ID: 11496328
[TBL] [Abstract][Full Text] [Related]
62. Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer.
Habermann H; Ray V; Habermann W; Prins GS
J Urol; 2001 Dec; 166(6):2267-72. PubMed ID: 11696749
[TBL] [Abstract][Full Text] [Related]
63. Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
Dema A; Tudose N
Rom J Morphol Embryol; 1998; 44(1-4):93-100. PubMed ID: 15678849
[TBL] [Abstract][Full Text] [Related]
64. High molecular weight cytokeratin antibody (clone 34betaE12): a sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer.
Varma M; Morgan M; Amin MB; Wozniak S; Jasani B
Histopathology; 2003 Feb; 42(2):167-72. PubMed ID: 12558749
[TBL] [Abstract][Full Text] [Related]
65. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Leav I; McNeal JE; Ho SM; Jiang Z
Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
[TBL] [Abstract][Full Text] [Related]
66. [Morphogenesis of benign prostatic hyperplasia and prostatic carcinoma].
Bonkhoff H; Remberger K
Pathologe; 1998 Jan; 19(1):12-20. PubMed ID: 9541938
[TBL] [Abstract][Full Text] [Related]
67. [The distribution of mast cells in benign and malignant prostate lesions and its biologic significance].
Deng WB; Li P; Li GX; Zhao Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Sep; 35(5):623-5. PubMed ID: 15460402
[TBL] [Abstract][Full Text] [Related]
68. Immunohistochemical Expression of Angiogenic Factors by Neoplastic Epithelial Cells Is Associated With Canine Prostatic Carcinogenesis.
Palmieri C
Vet Pathol; 2015 Jul; 52(4):607-13. PubMed ID: 25281650
[TBL] [Abstract][Full Text] [Related]
69. Lymphatic vessel density in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer assessed in whole-mount sections.
Longatto-Filho A; Malheiro LF; Milanezi F; Pinheiro C; Baltazar F; Schmitt FC; Montironi R
Anal Quant Cytol Histol; 2009 Oct; 31(5):269-75. PubMed ID: 20701093
[TBL] [Abstract][Full Text] [Related]
70. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
71. Immunoreactivity of ubiquitin in human prostate gland.
Bataineh ZM; Habbal O
Neuro Endocrinol Lett; 2006 Aug; 27(4):517-22. PubMed ID: 16892003
[TBL] [Abstract][Full Text] [Related]
72. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.
Markwalder R; Reubi JC
Cancer Res; 1999 Mar; 59(5):1152-9. PubMed ID: 10070977
[TBL] [Abstract][Full Text] [Related]
73. Role of androgen receptor in prostatic neoplasia versus hyperplasia.
Husain I; Shukla S; Soni P; Husain N
J Cancer Res Ther; 2016; 12(1):112-6. PubMed ID: 27072221
[TBL] [Abstract][Full Text] [Related]
74. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
Parsons JK; Gage WR; Nelson WG; De Marzo AM
Urology; 2001 Oct; 58(4):619-24. PubMed ID: 11597556
[TBL] [Abstract][Full Text] [Related]
75. Early over-expression of GRP receptors in prostatic carcinogenesis.
Körner M; Waser B; Rehmann R; Reubi JC
Prostate; 2014 Feb; 74(2):217-24. PubMed ID: 24150752
[TBL] [Abstract][Full Text] [Related]
76. Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia.
Montironi R; Lucarini G; Castaldini C; Galluzzi CM; Biagini G; Fabris G
Anticancer Res; 1996; 16(4A):2057-62. PubMed ID: 8712742
[TBL] [Abstract][Full Text] [Related]
77. Ghrelin receptor as a novel imaging target for prostatic neoplasms.
Lu C; McFarland MS; Nesbitt RL; Williams AK; Chan S; Gomez-Lemus J; Autran-Gomez AM; Al-Zahrani A; Chin JL; Izawa JI; Luyt LG; Lewis JD
Prostate; 2012 Jun; 72(8):825-33. PubMed ID: 21919027
[TBL] [Abstract][Full Text] [Related]
78. SIGIRR/TIR8, an important regulator of TLR4 and IL-1R-mediated NF-κB activation, predicts biochemical recurrence after prostatectomy in low-grade prostate carcinomas.
Bauman TM; Becka AJ; Sehgal PD; Huang W; Ricke WA
Hum Pathol; 2015 Nov; 46(11):1744-51. PubMed ID: 26344417
[TBL] [Abstract][Full Text] [Related]
79. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Young CY; Klee GG; Tindall DJ; Bostwick DG
Urology; 1997 Jun; 49(6):857-62. PubMed ID: 9187691
[TBL] [Abstract][Full Text] [Related]
80. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
Myers RB; Srivastava S; Oelschlager DK; Grizzle WE
J Natl Cancer Inst; 1994 Aug; 86(15):1140-5. PubMed ID: 7913137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
